skip to content
Primary navigation

Zyprexa Relprevv

DrugZyprexa® (olanzapine) Relprevv™

June 2014

Therapeutic Area - Mental health

FDA approved indication

Zyprexa Relprevv is a long-acting atypical antipsychotic for intramuscular injection indicated for the treatment of schizophrenia. 


  • Patient has a diagnosis of schizophrenia AND 
  • Patient is 18 years of age or older AND
  • Has shown a favorable response to oral olanzapine (Zyprexa) in efficacy measures AND
  • Has demonstrated poor compliance (> 30% missed doses) with oral olanzapine OR
  • Patient has been stabilized on Zyprexa Relprevv (the drug is part of the patient’s current course of treatment) as covered on a previous health insurance plan, and patient is new to MA OR
  • Patient was started and stabilized on Zyprexa Relprevv in an acute care setting, such as during a hospitalization, or within another place of care that offers acute care services

Zyprexa Relprevv is available only through a restricted distribution program.  

Zyprexa Relprevv must not be dispensed directly to a patient. 


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top